65,437 trials
Spinal Cord Injury · Muscle Spasticity
Primary: Double-blind Change From Baseline in Ashworth Score Evaluating Spasticity — -0.28; -0.16 units on a scale
Pain
Primary: Pain Scores During Overall IUD Placement — 2.12; 1.73 units on a scale of 0-9
Breast Cancer · Cancer Survivor · Hot Flashes
Primary: Percent Difference in Hot Flash Activity (Score) Between Baseline and End of Treatment (Week 5) — -50.4 percentage of difference
Alzheimer's Disease
Primary: Number of Participants With an Adverse Event (AE) — 8 participants
Breast Augmentation · Breast Reconstruction · Revision of Augmentation or Reconstruction
Primary: Local Complications — 9.2; 14.5; 11.9; 26.8 Percentage of Patients
Small/Large Bowel
Primary: Precentage of SB3 Images That Were Graded as Superior in Image Quality to SB2 by the Physicians — 98 percentage of cases
Delayed Graft Function · Acute Graft Rejection
Primary: Acute Rejection Rate at 12 Months — 48; 39 percentage of participants
Rheumatoid Arthritis
Primary: Maximum Observed Concentration (Cmax) of Single Dose Abatacept - Pharmacokinetic Evaluable Population — 262; 255 µg/mL
Glioblastoma · Gliosarcoma
Primary: 6-month Progression-free Survival (PFS) — 25; 28.6 percentage of participants
Prostate Cancer
Primary: Pathologic Complete Response Was Assessed by Rigorous Pathological Examination by One of Two Pathologists — 0 participants
Lung Cancer
Primary: Progression Free Survival(PFS) — 5.6 months
Kidney Neoplasms
Primary: Progression Free Survival (PFS): First-Line Participants — 10.1; 6.5 months
Edema, Cardiac
Primary: Body Weight (Amount of Change) — -0.45; -1.54 Kg — p=<0.0001
Stress Disorders, Post-traumatic
Primary: Post-Traumatic Stress Disorder Checklist-Military Version (PCL-M) — 57.14; 61.33; 52.21; 53.78 units on a scale
Pulmonary Disease, Chronic Obstructive
Primary: Change in Muscle Sympathetic Nerve Activity (MSNA) at 2 Hours (Week 0) — -1.3 Bursts/100 heart beats — p=0.5062